At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox® Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study)
In Brief
A Phase 1 clinical trial evaluating Aggrenox alone, Aggrenox and omeprazole, and 1 other intervention for Healthy. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics of dipyridamole and the pharmacodynamics of ASA-induced platelet aggregation inhibition (components of Aggrenox®) when administered every 12 hours at steady state.
Study Details
Timeline
Interventions
Aggrenox 1 capsule twice daily for 7 days
Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
omeprazole 80 once daily for 7 days